343 related articles for article (PubMed ID: 17767471)
1. Chromogranin A in patients with acid hypersecretion and/or hypergastrinaemia.
Hirschowitz BI; Worthington J; Mohnen J; Haber M
Aliment Pharmacol Ther; 2007 Sep; 26(6):869-78. PubMed ID: 17767471
[TBL] [Abstract][Full Text] [Related]
2. Helicobacter pylori effects on gastritis, gastrin and enterochromaffin-like cells in Zollinger-Ellison syndrome and non-Zollinger-Ellison syndrome acid hypersecretors treated long-term with lansoprazole.
Hirschowitz BI; Haber MM
Aliment Pharmacol Ther; 2001 Jan; 15(1):87-103. PubMed ID: 11136282
[TBL] [Abstract][Full Text] [Related]
3. Histopathology of the gastric oxyntic mucosa in two different patient groups during long-term treatment with omeprazole.
Hage E; Hendel L; Gustafsen J; Hendel J
Eur J Gastroenterol Hepatol; 2003 Jul; 15(7):781-9. PubMed ID: 12811309
[TBL] [Abstract][Full Text] [Related]
4. Consequences of long-term proton pump blockade: insights from studies of patients with gastrinomas.
Jensen RT
Basic Clin Pharmacol Toxicol; 2006 Jan; 98(1):4-19. PubMed ID: 16433886
[TBL] [Abstract][Full Text] [Related]
5. Long-term treatment with lansoprazole for patients with Zollinger-Ellison syndrome.
Hirschowitz BI; Mohnen J; Shaw S
Aliment Pharmacol Ther; 1996 Aug; 10(4):507-22. PubMed ID: 8853754
[TBL] [Abstract][Full Text] [Related]
6. Case presentation of gastrinoma combined with gastric carcinoid with the longest survival record -- Zollinger-Ellison syndrome: pathophysiology, diagnosis and therapy.
Konturek SJ; Konturek PC; Bielański W; Lorens K; Sito E; Konturek JW; Kwiecień S; Bobrzyński A; Pawlik T; Karcz D; Areny H; Stachura T
Med Sci Monit; 2002 Jun; 8(6):CS43-59. PubMed ID: 12070442
[TBL] [Abstract][Full Text] [Related]
7. Clinical aspects of ECL-cell abnormalities.
Hirschowitz BI
Yale J Biol Med; 1998; 71(3-4):303-10. PubMed ID: 10461361
[TBL] [Abstract][Full Text] [Related]
8. Zollinger Ellison syndrome, treated with lansoprazole, during pregnancy.
Mayer A; Sheiner E; Holcberg G
Arch Gynecol Obstet; 2007 Aug; 276(2):171-3. PubMed ID: 17318560
[TBL] [Abstract][Full Text] [Related]
9. Progression of gastric enterochromaffin-like cells growth in Zollinger-Ellison syndrome and atrophic body gastritis patients.
Delle Fave G; Marignani M; Corleto VD; Angeletti S; D'Ambra G; Ferraro G; D'Adda T; Azzoni C; Jensen RT; Annibale B; Bordi C
Dig Liver Dis; 2002 Apr; 34(4):270-8. PubMed ID: 12038811
[TBL] [Abstract][Full Text] [Related]
10. Zollinger-Ellison syndrome: presentation, response to therapy, and outcome.
Wilcox CM; Seay T; Arcury JT; Mohnen J; Hirschowitz BI
Dig Liver Dis; 2011 Jun; 43(6):439-43. PubMed ID: 21193359
[TBL] [Abstract][Full Text] [Related]
11. Pathobiology and management of hypergastrinemia and the Zollinger-Ellison syndrome.
Hirschowitz BI
Yale J Biol Med; 1992; 65(6):659-76; discussion 689-92. PubMed ID: 1341070
[TBL] [Abstract][Full Text] [Related]
12. Presentation, response to lansoprazole therapy, and outcome of Zollinger-Ellison syndrome-like gastric acid hypersecretors.
Wilcox CM; Seay T; Arcury J; Hirschowitz BI
Scand J Gastroenterol; 2011 Mar; 46(3):277-80. PubMed ID: 21073392
[TBL] [Abstract][Full Text] [Related]
13. Prospective study of the value of serum chromogranin A or serum gastrin levels in the assessment of the presence, extent, or growth of gastrinomas.
Goebel SU; Serrano J; Yu F; Gibril F; Venzon DJ; Jensen RT
Cancer; 1999 Apr; 85(7):1470-83. PubMed ID: 10193936
[TBL] [Abstract][Full Text] [Related]
14. Prospective study of the ability of histamine, serotonin or serum chromogranin A levels to identify gastric carcinoids in patients with gastrinomas.
Bashir S; Gibril F; Ojeaburu JV; Asgharian B; Entsuah LK; Ferraro G; Crafa P; Bordi C; Jensen RT
Aliment Pharmacol Ther; 2002 Jul; 16(7):1367-82. PubMed ID: 12144588
[TBL] [Abstract][Full Text] [Related]
15. Gastric carcinoids in patients with hypergastrinemia.
Jordan PH; Barroso A; Sweeney J
J Am Coll Surg; 2004 Oct; 199(4):552-5. PubMed ID: 15454137
[TBL] [Abstract][Full Text] [Related]
16. Long-term treatment with lansoprazole of patients with duodenal ulcer and basal acid output of more than 15 mmol/h.
Hirschowitz BI; Mohnen J; Shaw S
Aliment Pharmacol Ther; 1996 Aug; 10(4):497-506. PubMed ID: 8853753
[TBL] [Abstract][Full Text] [Related]
17. Long-term lansoprazole control of gastric acid and pepsin secretion in ZE and non-ZE hypersecretors: a prospective 10-year study.
Hirschowitz BI; Simmons J; Mohnen J
Aliment Pharmacol Ther; 2001 Nov; 15(11):1795-806. PubMed ID: 11683694
[TBL] [Abstract][Full Text] [Related]
18. Hypergastrinemia and enterochromaffin-like cell hyperplasia.
Delle Fave G; Marignani M; Moretti A; D'Ambra G; Martino G; Annibale B
Yale J Biol Med; 1998; 71(3-4):291-301. PubMed ID: 10461360
[TBL] [Abstract][Full Text] [Related]
19. Treatment of ECL cell carcinoids with octreotide LAR.
Fykse V; Sandvik AK; Qvigstad G; Falkmer SE; Syversen U; Waldum HL
Scand J Gastroenterol; 2004 Jul; 39(7):621-8. PubMed ID: 15370681
[TBL] [Abstract][Full Text] [Related]
20. An open-label study of rabeprazole in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion.
Morocutti A; Merrouche M; Bjaaland T; Humphries T; Mignon M
Aliment Pharmacol Ther; 2006 Nov; 24(10):1439-44. PubMed ID: 17081164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
